Human epidermal growth factor receptor 2 (HER2) - Specific chimeric antigen receptor - Modified T cells for the immunotherapy of HER2-positive sarcoma

Journal of Clinical Oncology

Volumn 33, Issue 15, 2015, Pages 1688-1696

  Ahmed, Nabil ^a,b   Brawley, Vita S ^a,b   Hegde, Meenakshi ^a,b   Robertson, Catherine ^a,b   Ghazi, Alexia ^a,b   Gerken, Claudia ^a,b   Liu, Enli ^a,b   Dakhova, Olga ^a,b   Ashoori, Aidin ^a,b   Corder, Amanda ^a,b   Gray, Tara ^a,b   Wu, Meng Fen ^b   Liu, Hao ^b   Hicks, John ^b   Rainusso, Nino ^b   Dotti, Gianpietro ^a,b   Mei, Zhuyong ^a,b   Grilley, Bambi ^a,b   Gee, Adrian ^a,b   Rooney, Cliona M ^a,b   Brenner, Malcolm K ^a,b   Heslop, Helen E ^a,b   Wels, Winfried S ^e   Wang, Lisa L ^b   Anderson, Peter ^c,d   Gottschalk, Stephen ^a,b   more..

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d LEVINE CANCER INSTITUTE   (United States)

^e INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CHILD; CLINICAL ARTICLE; DESMOPLASTIC SMALL ROUND CELL TUMOR; EWING SARCOMA; FEMALE; HUMAN; LYMPHOCYTE HOMING; MALE; NEUROECTODERM TUMOR; OSTEOSARCOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOMA; T LYMPHOCYTE; TREATMENT RESPONSE; BONE NEOPLASMS; CHEMISTRY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; KAPLAN MEIER METHOD; MAXIMUM TOLERATED DOSE; METABOLISM; METASTASIS; NEUROECTODERMAL TUMORS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; RECURRENT DISEASE; SARCOMA, EWING; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; BONE NEOPLASMS; CHILD; FEMALE; HUMANS; IMMUNOTHERAPY; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MAXIMUM TOLERATED DOSE; NEOPLASM METASTASIS; NEUROECTODERMAL TUMORS; OSTEOSARCOMA; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, ERBB-2; RECEPTORS, ANTIGEN, T-CELL; RECURRENCE; SARCOMA; SARCOMA, EWING; T-LYMPHOCYTES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84933513655     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.58.0225     Document Type: Article

References (42)

1. Linch M, Miah AB, Thway K, et al: Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies. Nat Rev Clin Oncol 11:187-202, 2014
2. Bielack SS, Carrle D, Hardes J, et al: Bone tumors in adolescents and young adults. Curr Treat Options Oncol 9:67-80, 2008
3. Meyers PA: High-dose therapy with autologous stem cell rescue for pediatric sarcomas. Curr Opin Oncol 16:120-125, 2004
4. Finkelstein SE, Fishman M, Conley AP, et al: Cellular immunotherapy for soft tissue sarcomas. Immunotherapy 4:283-290, 2012
5. Buddingh EP, Schilham MW, Ruslan SE, et al: Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells. Cancer Immunol Immunother 60: 575-586, 2011
6. Rainusso N, Brawley VS, Ghazi A, et al: Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma. Cancer Gene Ther 19:212-217, 2012
7. Kalos M, Levine BL, Porter DL, et al: T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3:95ra73, 2011
8. Grupp SA, Kalos M, Barrett D, et al: Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368:1509-1518, 2013
9. Brentjens RJ, Davila ML, Riviere I, et al: CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5:177ra38, 2013
10. Kochenderfer JN, Dudley ME, Feldman SA, et al: B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119:2709-2720, 2012
11. Pule MA, Savoldo B, Myers GD, et al: Virusspecific T cells engineered to coexpress tumorspecific receptors: Persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14:1264-1270, 2008
12. Park JR, Digiusto DL, Slovak M, et al: Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 15:825-833, 2007
13. Dotti G, Gottschalk S, Savoldo B, et al: Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev 257: 107-126, 2014
14. Ahmed N, Salsman VS, Yvon E, et al: Immunotherapy for osteosarcoma: Genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther 17:1779-1787, 2009
15. Roth M, Linkowski M, Tarim J, et al: Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma. Cancer 120:548-554, 2014
16. Huang G, Yu L, Cooper LJ, et al: Genetically modified T cells targeting interleukin-11 receptor alpha-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases. Cancer Res 72:271-281, 2012
17. Modak S, Kramer K, Gultekin SH, et al: Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors. Cancer Res 61:4048-4054, 2001
18. Gorlick R, Huvos AG, Heller G, et al: Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 17:2781-2788, 1999
19. Somers GR, Ho M, Zielenska M, et al: HER2 amplification and overexpression is not present in pediatric osteosarcoma: A tissue microarray study. Pediatr Dev Pathol 8:525-532, 2005
20. Ebb D, Meyers P, Grier H, et al: Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: A report from the children's oncology group. J Clin Oncol 30:2545-2551, 2012
21. Morgan RA, Yang JC, Kitano M, et al: Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18: 843-851, 2010
22. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
23. Ahmed N, Ratnayake M, Savoldo B, et al: Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res 67:5957-5964, 2007
24. Ahmed N, Salsman VS, Kew Y, et al: HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res 16:474-485, 2010
25. Bernhard H, Neudorfer J, Gebhard K, et al: Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. Cancer Immunol Immunother 57:271-280, 2008
26. Disis M, Salazar LG, Coveler A, et al: Phase I study of infusion of HER2/neu (HER2) specific T cells in patients with advanced-stage HER2 overexpressing cancers who have received a HER2 vaccine. J Clin Oncol 27, 2009 (suppl 15s, abstr 3000)
27. Milone MC, Fish JD, Carpenito C, et al: Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 17:1453-1464, 2009
28. Cho HS, Mason K, Ramyar KX, et al: Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421:756-760, 2003
29. Gerstmayer B, Altenschmidt U, Hoffmann M, et al: Costimulation of T cell proliferation by a chimeric B7-2 antibody fusion protein specifically targeted to cells expressing the erbB2 protooncogene. J Immunol 158:4584-4590, 1997
30. Louis CU, Savoldo B, Dotti G, et al: Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118:6050-6056, 2011
31. Porter DL, Levine BL, Kalos M, et al: Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365:725-733, 2011
32. Savoldo B, Ramos CA, Liu E, et al: CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 121:1822-1826, 2011
33. Jensen MC, Popplewell L, Cooper LJ, et al: Anti-transgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant 16:1245-1256, 2010
34. Lamers CH, Willemsen R, van Elzakker P, et al: Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 117:72-82, 2011
35. Blum KS, Pabst R: Lymphocyte numbers and subsets in the human blood: Do they mirror the situation in all organs? Immunol Lett 108:45-51, 2007
36. Craddock JA, Lu A, Bear A, et al: Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother 33:780-788, 2010
37. Hoos A, Eggermont AM, Janetzki S, et al: Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 102:1388-1397, 2010
38. Bielack SS, Kempf-Bielack B, Branscheid D, et al: Second and subsequent recurrences of osteosarcoma: Presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol 27:557-565, 2009
39. Kempf-Bielack B, Bielack SS, Jürgens H, et al: Osteosarcoma relapse after combined modality therapy: An analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 23:559-568, 2005
40. Bacci G, Briccoli A, Longhi A, et al: Treatment and outcome of recurrent osteosarcoma: Experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol 44:748-755, 2005
41. Di Stasi A, Tey SK, Dotti G, et al: Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365:1673-1683, 2011
42. Fedorov VD, Themeli M, Sadelain M: PD-1-and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med 5:215ra172, 2013